• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction.
【24h】

Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction.

机译：吸入糖皮质激素治疗慢性气流阻塞的老年患者发生青光眼的风险。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Topical and systemic corticosteroids are well known to raise intra-ocular pressure while the effect of inhaled corticosteroids (ICS) on the risk of glaucoma remains uncertain. We sought to determine the risk of new onset ocular hypertension or glaucoma requiring treatment, associated with the use of ICS in elderly patients treated for airways disease. METHODS: We carried out a nested case-control study using the databases from the Quebec provincial health insurance plan. A cohort of patients receiving respiratory medications was formed among all subjects 66 years of age and older. Cases were subjects in whom treatment for glaucoma was initiated between January 1, 1988 and December 31, 2003 after a first ever visit to an ophthalmologist within the preceding 90 days. Age-matched controls were selected among individuals who also visited an ophthalmologist for the first time within 90 days of the case's treatment date and did not receive a treatment for glaucoma. RESULTS: A total of 2291 cases were identified. For comparison, a total of 13,445 age-matched controls were selected. The mean age was (75+/-4.2 years). The adjusted rate ratio for glaucoma was 1.05 (95% CI 0.91-1.20) with ICS use in the preceding 30 days. There was no dose-related effect of ICS on the risk of glaucoma or raised intra-ocular pressure requiring treatment. Continuous use of high-dose ICS for 3 of more months was not associated with an increased risk of glaucoma. CONCLUSION: In a large cohort of elderly patients treated for airways disease, we found that current use and continuous use of high-dose ICS did not result in an increased risk of glaucoma or raised intra-ocular pressure requiring treatment.
机译：背景：众所周知，局部和全身性皮质类固醇会增加眼内压，而吸入性皮质类固醇（ICS）对青光眼风险的影响尚不确定。我们试图确定需要治疗的新发高眼压或青光眼的风险，以及在接受气道疾病治疗的老年患者中使用ICS的风险。方法：我们使用魁北克省健康保险计划中的数据库进行了嵌套病例对照研究。在66岁及以上的所有受试者中形成了接受呼吸系统药物治疗的患者队列。在过去90天内首次拜访眼科医生之后，从1988年1月1日至2003年12月31日开始对青光眼进行治疗的受试者为对象。从年龄相同的对照组中选择谁，该组患者在该病例的治疗日期后90天内首次拜访了眼科医生，并且未接受青光眼的治疗。结果：共鉴定出2291例。为了进行比较，总共选择了13445个年龄匹配的对照。平均年龄为（75 +/- 4.2岁）。青光眼的调整后比率为1.05（95％CI 0.91-1.20），前30天使用ICS。 ICS对青光眼或需要治疗的眼内压升高风险无剂量相关作用。连续使用高剂量ICS超过3个月与增加的青光眼风险无关。结论：在一大批接受气道疾病治疗的老年患者中，我们发现当前使用和持续使用大剂量ICS不会导致青光眼的风险增加或需要治疗的眼内压升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号